Brian Roberts, MD

Rezolute, Inc
Redwood City, California, United States

Disclosure information not submitted.

Presentation(s):

• SAT-087 - A Case Series on the Compassionate Use of Ersodetug, an Insulin Receptor Modulating Antibody, in Patients with Refractory Hypoglycemia Due to Malignant Insulin-Secreting Tumors

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• SAT-221 - Association of Early-Life Hypoglycemia with Later Neurological Outcomes in Congenital Hyperinsulinism: A US Claims-Based Study

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT

• ORF10-06 - Ersodetug (RZ358) in Congenital Hyperinsulinism: Top-Line Results from a Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (sunRIZE)

  Saturday, June 13, 2026
  2:30 PM - 2:45 PM CT

• MON-215 - Outcomes in Congenital Hyperinsulinism: A Systematic Review

  Monday, June 15, 2026
  9:00 AM - 2:00 PM CT